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Epidermal growth factor receptor (EGFR) supports colorectal cancer pro-
gression via oncogenic signaling. Anti-EGFR therapy is being investigated
as a clinical option for colorectal cancer, and an observed interaction
between EGFR and Prion protein has been detected in neuronal cells. We
hypothesized that PrPC expression levels may regulate EGFR signaling and
that detailed understanding of this signaling pathway may enable identifi-
cation of resistance mechanisms and new actionable targets in colorectal
cancer. We performed molecular pathway analysis following knockdown of
PrPC or inhibition of EGFR signaling via gefitinib to identify changes in
expression of key signaling proteins that determine cellular sensitivity or
resistance to cisplatin. Expression of these proteins was examined in
matched primary and metastatic patient samples and was correlated for
resistance to therapy and progression of disease. Utilizing three colorectal
cancer cell lines, we observed a correlation between high expression of
PrPC and resistance to cisplatin. Investigation of molecular signaling in a
resistant cell line revealed that PrPC contributed to signaling via colocaliza-
tion with EGFR, which could be overcome by targeting p38 mitogen-acti-
vated protein kinases (p38 MAPK). We revealed that the level of
Kr€uppel-like factor 5 (KLF5), a target downstream of p38 MAPK, was
predictive for cell line and patient response to platinum agents. Further,
high KLF5 expression was observed in BRAF-mutant colorectal cancer.
Our study indicates that the EGFR to KLF5 pathway is predictive of
patient progression on platinum-based therapy.
1. Introduction
Platinum-based therapy is frontline for colorectal
cancer. The use of fluorouracil, leucovorin plus oxali-
platin (FOLFOX) has seen advances in overall clinical
response for aggressive colorectal cancer, with patient
survival extended beyond 2 years (Fuchs et al., 2007).
However, chemoresistance, clinical relapse, and metas-
tasis have become more prevalent with extended courses
of therapy. The use of alternative complementary
Abbreviations
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targets including epidermal growth factor receptor
(EGFR) has been suggested; however, the mechanisms
underlying EGFR and its potential role in chemoresis-
tance to platinum-based therapy are not fully under-
stood. In this study, we elucidate the molecular signaling
downstream of EGFR and its binding partner Prion
protein (PrPC) that contribute to platinum resistance
and development of metastases in patients.
The noninfectious cellular PrPC, encoded by the
PRNP gene, is a protein of unknown precise function
(Mehrpour and Codogno, 2010). PrPC is involved in
the progression of a number of cancers, including col-
orectal (Liang et al., 2006; Mehrpour and Codogno,
2010), breast (Diarra-Mehrpour et al., 2004; Vassallo
et al., 2005), gastric (Liang et al., 2006, 2007; Pan
et al., 2006), and pancreatic (Li et al., 2009a), as well
as potentially supporting drug resistance in gastric and
breast cancers (Du et al., 2005; Li et al., 2009b). PrPC
is found mainly as a glycophosphatidylinositol-
anchored cell surface protein in lipid rafts. Association
of PrPC with signaling receptors in lipid rafts can
either enhance or inhibit oncogenic signaling. The
binding of EGFR by PrPC and inhibition of subse-
quent signaling pathway have significant implications
on cellular response to therapies. There is evidence
that phosphatidylinositol 3-kinase (Pi3K) signaling
induces PrPC expression by inhibition of the repressive
action of the forkhead/winged helix box class O
(FOXO) transcription factors on PrPC expression (Liu
et al., 2013). FOXO3a is a downstream effector of
EGFR and the PI3K pathway, which via p38 mitogen-
activated protein kinase (MAPK) inhibition can induce
cell cycle arrest and is a key mediator of the cytotoxic
effect of cisplatin in colorectal cancer (Fernandez de
Mattos et al., 2008; Germani et al., 2014). We specu-
late that PrPC can influence cisplatin resistance in col-
orectal cancer via EGFR signaling to p38 MAPK and
regulation of expression of FOXO3a. Further, we pro-
pose that Kr€uppel-like factor 5 (KLF5), the down-
stream effector of this pathway, promotes cisplatin/
oxaliplatin resistance supporting metastasis in colorec-
tal cancer patients.
2. Materials and methods
2.1. Cell culture
HT29, SW620, and T84 cell lines (ATCC, Noble Park,
Australia) were cultured at 37 °C with 5% CO2 in
high-glucose Dulbecco’s modified Eagle’s medium
(Invitrogen) supplemented with 10% FBS (Invitrogen,
Scoresby, Australia) and a 1% penicillin/streptomycin
cocktail (Invitrogen).
2.2. Immunofluorescence
Immunofluorescence microscopy was performed as
previously described (Ham et al., 2016). Coverslips
were incubated overnight at 4 °C with primary anti-
bodies specific to PrPC (3F4 Millipore, Bayswater,
Australia) or EGFR (Ab2 Sigma, Castle Hill, Austra-
lia) (1 : 500 with PBS), washed with ice-cold PBS, and
stained with secondary anti-mouse fluorophore-labeled
antibodies (1 : 5000 Sigma). Coverslips were mounted
with ProLong Gold Antifade Mountant with DAPI
liquid mountant (Life Technologies, Scoresby, Austra-
lia). Images were taken on a Zeiss 780-NLO confocal
microscope (Carl Zeiss Microscopy, North Ryde,
Australia) with 40x and 100x magnifications.
2.3. Immunoblotting and immunoprecipitation
Immunoblots were probed with anti-PrPC (Millipore),
anti-FOXO3a (Abcam, Melbourne, Australia), anti-phos-
pho-FOXO3a (Abcam), anti-AKT (Cell Signaling),
anti-phospho-AKT (Cell Signaling, Arundel, Austra-
lia), anti-p38 MAPK (Cell Signaling), anti-phospho-
p38 MAPK (Cell Signaling), and anti-KLF5 (R&D
Systems, Noble Park, Australia). Histone H3 (Cell Sig-
naling) or a-tubulin (Sigma) was used as loading con-
trol. Membrane fraction of cell lysates (100 lg) were
incubated in the presence of 2 lg of either anti-PrPC
(Millipore), anti-EGFR (Cell Signaling), or IgG iso-
type control antibody overnight at 4 °C with mixing.
To each immunoprecipitation 60 lL of Protein A/G
agarose bead slurry (Millipore) was added and incu-
bated with mixing for 2 h at room temperature. The
beads were spun down and washed five times with ice
cold PBS. The final spin was resuspended in SDS/
PAGE loading buffer and 5 lL loaded per well. Anti-
HSP70 was used as a loading control for 1% input.
2.4. Drug dose curves
IC50 calculated using dose–response curves with cis-
platin (0, 3, 10, 30, 100, and 300 lM), LY2228820 (0, 1,
3, 10, 30, and 100 lM), and gefitinib (0, 0.01, 0.1, 1, 10,
and 100 lM) and analyzed for effects on cell viability via
MTS assay after 72 h (Sigma, Castle Hill, Australia).
Absorbance of samples was measured at 500 nm, and
the percentage of viable cells was calculated using PRISM
software (GraphPad, San Diego, CA, USA).
2.5. Gene silencing
HT29 and SW620 cells were seeded at 1.5 9 105
cells per 35 mm well and incubated overnight. The
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cells were then transfected with siRNA using Lipo-
fectamine 2000 in OptiMEM for 6 h. siRNA used
include ON-TARGETplus human PrPC (Dharmacon,
Sydney, Australia), human KLF5 (Dharmacon), and
universal negative control (Sigma-Aldrich, Castle
Hill, Australia), at a final concentration of 10 nM.
2.6. Quantitative real-time polymerase chain
reaction
RNA was isolated using RNeasy Mini Kit (Qiagen,
Chadstone, Australia). cDNA was synthesized using
RT2 First Strand Kit (Qiagen). cDNA was analyzed on
LightCycler 480 (Roche, North Ryde, Australia) with
validated primer sets (Table S1). Fold expression change
was calculated against b-actin and expressed as base-two
exponential increase in RNA levels (2DDCt )  SEM.
2.7. Immunohistochemistry
Sections (3–4 lm) were deparaffinized and blocked in
BSA for 15 min, and then incubated in primary anti-
body (1 : 500 with PBS) overnight at 4 °C. Sections
were washed and MACH 1 Universal HRP-Polymer
Detection (Biocare Medical, Redcliffe, Australia)
applied for 30 min. Sections were washed, and signal
was developed in Betazoid DAB (Biocare Medical) for
5 min, and then washed in gently running tap water for
5–10 min to remove excess chromogen. Sections were
then lightly counterstained in Mayer’s hematoxylin, and
then dehydrated through ascending graded ethanol,
cleared in xylene, and mounted using DPX (Sigma-
Aldrich). Staining was interpreted by a pathologist
(CL), who scored PrPC, FOXO3a, and KLF5 staining
based on three criteria—intensity (nil, weak, moderate,
or strong), localization (nuclear or cytoplasmic), and
percentage (divided into 5% intervals). Weak staining
was defined as visible at 4009 magnification, moderate
staining as visible at 1009 magnification, and strong
staining as visible at 209 magnification. Nuclear stain-
ing and cytoplasmic staining were assessed sepa-
rately. Staining percentage was estimated and rounded
to the closest 5%. For example, a tumor may have a
result of ‘weak cytoplasmic staining in 45% of cells’.
These semiquantitative measurements were converted to
a final staining percentage.
2.8. Statistics
Results are presented as mean  SEM of replicate
analyses and are either representative of or inclusive of
at least three independent experiments. All statistical
analyses were performed using two-tailed Student’s
t-tests in GRAPHPAD PRISM 7 software. In all figures,
significant differences between specified pair of condi-
tions, as judged by t-test, are indicated using asterisks
(*P < 0.05; **P < 0.005, ***P < 0.001). IC50 doses
were calculated by interpolation of the sigmoidal
dose–response curves (GRAPHPAD PRISM 7.0 software).
2.9. Human tissue samples
Formalin-fixed, paraffin-embedded tissue samples
from 11 patients who had undergone surgery for col-
orectal cancer and matched liver metastasis between
2003 and 2014 Hokkaido University Hospital were
utilized in this study. Clinicopathological information
is summarized in Table 1. Formalin-fixed, paraffin-
embedded tissue samples from 30 patients that under-
went surgery between 2011 and 2012, and their MSI
Table 1. Changes in PrPC-FOXO3a-KLF5 expression in metastases determine patient outcome.
Patient
T/N
scoring
Stage
at
diagnosis
Adjuvant
chemotherapy
Chemotherapy
for metastasis
Outcome
(month)
PrPC change
colon vs
Met (%)
Foxo change
colon vs
Met (%)
KLF5 change
colon vs
Met (%)
1 T4a/N2 IV NONE mFOLFOX6 Dead (36) 5 65 0
5 T3/N1 III mFOLFOX6 FOLFIRI Dead (42) 1 60 1
6 T3/N2 IV NONE mFOLFOX6 Dead (24) 30 10 0
2 T3/N0 II XELOX XELOX Dead (13) 25 20 15
7 T3/N2 IV mFOLFOX6 FOLFIRI Dead (28) 0 45 4
3 T3/N1 IV NONE PMC Alive (138) 5 15 0
4 T3/N2 IV NONE mFOLFOX6 Alive (14) 1 20 9
8 T3/N0 IV NONE mFOLFOX6 Alive (12) 1 30 9
9 T2/N0 II NONE TS1 Alive (96) 0 10 4
10 T3/N1 IV NONE UFT+LV Alive (102) 5 0 4
11 T3/N0 IV UFT NA NA 5 15 0
Light grey: poor patient outcome based on increased FOXO3a expression. Dark grey: poor patient outcome based on increased KLF5
expression.
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statuses were evaluated for BRAFV600E mutation
was screened on DNA extracted by the Chelex-100
method (Bio-Rad Laboratories, Hercules, CA, USA)
using an allelic discrimination assay and KRAS
mutation was assessed using High Resolution Melt
technology (Whitehall et al., 2009).
Fig. 1. Prion protein associates with EGFR. (A) Western blot analysis of PrPC expression in HT29, SW620, T84, and ‘normal-like’ 293T cell
lines. b-Actin serves as a loading control. (B) Cisplatin dose–response curves of HT29, SW620, and T84 cell lines. Solid lines indicate
normalized nonlinear fit and error bars  SEM. (C) HT29, SW620, and T84 response to cisplatin treatment with or without PrPC knockdown
and p38 MAPK inhibitor. Cell viability was determined by MTS (% viability relative to DMSO control  SEM and significance measured by
two-tailed Student’s t-test *P < 0.05). (D) Subcellular localization of PrPC (green), EGFR (red), and nuclei-stained DAPI (blue), scale bar
100 lM. (E) Fluorescence signal intensity of PrPC and EGFR in HT29 cells, indicating colocalization. (F) Immunoprecipitation of PrP and EGFR
by reciprocal antibodies. HSP70 probed for 1% of lysate input. (G) RNA-seq analysis of 452 colon patient samples for correlation between
PrPC and EGFR expression levels and patient outcome (significance determined by logrank test). All data are the means of three
independent biological replicates and error bars  SEM. PRNPsi, PrPC knockdown; p38i, p38 MAPK inhibitor.
728 Molecular Oncology 13 (2019) 725–737 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
EGFR and Prion protein signaling determines response C. J. Atkinson et al.
2.10. Human gene expression data
Analysis was performed using RNA-seq data of 452
colon patient samples obtained from the TCGA repos-
itory. In the survival analysis, no restrictions based on
gender, race, stage, grade, or molecular subtype were
applied. A database with Affymetrix gene chips was
set up as described previously (PMID: 27849044). In
this, the analysis on gene expression was performed on
1211 patient samples restricted to Grade 3 tumors.
Cox proportional hazards survival analysis was per-
formed using each cutoff between the lower and upper
quartiles, and the best performing cutoff was used to
draw a Kaplan–Meier plot. The utilized probes were
1956 (EGFR) and 5621 (PRNP) in the RNA-seq data-
set and 209212_s_at (KLF5) and 210655_s_at
(FOXO3A) in the Affymetrix dataset.
2.11. Study approval
All patients in this study provided written informed
consent. Approval was obtained from Hokkaido
University Human Research Ethics committee (HREC
14-005) and QIMRB Human Research Ethics commit-
tee (HREC P1239 and P1278). The study methodolo-
gies conformed to the standards set by the Declaration
of Helsinki.
3. Results
3.1. PrPC overexpression promotes cisplatin
resistance
High PrPC expression levels can promote chemoresis-
tance and cancer progression by functions that include
protein–protein interactions and transcriptional regula-
tion (Cheng et al., 2014; Li et al., 2009b; Meslin et al.,
2007; Zhao et al., 2002). Direct comparison of protein
expression in colorectal cancer cell lines HT29,
SW620, and T84 revealed 3.8-fold overexpression of
PrPC in HT29 cells relative to the ‘normal-like’ 293T
cell line (Fig. 1A), which correlated with resistance to
cisplatin (Fig. 1B). Cisplatin resistance in colorectal
cancer is promoted by p38 MAPK signaling (Pereira
et al., 2013). Inhibition of p38 MAPK has been shown
to enhance the effects of cisplatin by activation of
FOXO3a (Pereira et al., 2013). PrPC promotes inhibi-
tion of FOXO3a activity to generate chemoresistance
in neuroblastoma (Liu et al., 2013). We hypothesized
PrPC-mediated cisplatin resistance could be overcome
by targeting p38 MAPK in a combination therapy
with depletion of PrPC expression. We previously
determined the use of p38 MAPK inhibitor
LY2228820 alone does not affect viability in vitro or
affect tumor development of MDA-MB-231 breast
cancer cells in vivo (Wiegmans et al., 2016). These cells
express comparable levels of PrPC to that observed in
HT29 cells (Fig. S1A). Comparison of the colorectal
cell lines revealed that only the low PrPC-expressing
T84 cell line was sensitive to LY2228820 (Fig. S1B).
Of note, PrPC knockdown alone (Fig. S1C) did not
significantly overcome cisplatin resistance (Fig. 1C).
However, addition of low-dose p38 MAPK inhibitor
significantly sensitized HT29 cells to cisplatin
(Fig. 1C). This suggests that p38 MAPK is a major
contributor to cisplatin resistance observed in the
HT29 cell line. In colorectal cancer, p38 MAPK acti-
vation can be driven by EGFR (Grossi et al., 2014).
We hypothesized that PrPC supports EGFR activation
and could be a marker for patient response to plat-
inum therapy.
3.2. PrPC and EGFR are associated in colorectal
cells and are markers for patient outcome in
colon cancer
Enhanced EGFR signaling in colorectal cancer pro-
motes proliferation and cancer progression (Cohen,
2003; Salomon et al., 1995). PrPC colocalizes with
EGFR in lipid rafts and regulates EGFR function in
neuronal cells (Llorens et al., 2013). We observed mem-
brane expression of PrPC and EGFR in HT29 cells
(Fig. 1D), to a lesser extent in SW620 cells (Fig. S2A)
and no detectable expression in T84 cells (data not
shown). The two proteins colocalized at the cell mem-
brane of HT29 cells when PrPC was endogenously over-
expressed (Fig. 1E), and each protein could be
immunoprecipitated by the other in HT29 cells
(Fig. 1F) and the smallest isoform of PrPC by EGFR
in SW620 cells (Fig. S2B). Examination of 452 colon
patient samples for correlation between PrPC and
EGFR expression levels and patient outcome revealed
that higher PrPC expression is strongly associated with
poor outcome, whereas EGFR was not (Fig. 1G).
Coexpression of both PrPC and EGFR was more sig-
nificant than PrPC alone and higher hazard ratio sug-
gesting EGFR does contribute to poor patient outcome
when PrPC is overexpressed (Fig. 1G-right panel).
3.3. Targeting p38 MAPK with depletion of PrPC
or targeting of EGFR overcome cisplatin
resistance but through different signaling
pathways
Inhibition of EGFR signaling with gefitinib results in
growth delay of cancer cell lines expressing high levels
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of EGFR via activating FOXO3a by dephosphoryla-
tion, thus allowing its nuclear translocation (Krol
et al., 2007). We investigated whether inhibition of
EGFR would mimic PrPC knockdown. The addition
of gefitinib alone (Fig. S3) or in combination with cis-
platin had no significant effect on any of the cell lines
(Fig. 2A). Further addition of p38 MAPK inhibitor
overcame cisplatin resistance in HT29 cells, similar to
what was observed with PrPC knockdown (Fig. 2A).
We examined whether the contribution of p38 MAPK
inhibition was the main driver of sensitivity for PrPC
knockdown or gefitinib and found that in the absence
of cisplatin, PrPC knockdown was ineffective with p38
inhibition, while gefitinib sensitized to p38 inhibition
(Fig. 2B). We observed the same results with the dual
EGFR/HER2 inhibitor afatinib (Fig. S4A,B). This
indicates that PrPC expression directly contributes to
cisplatin resistance independent of EGFR signaling,
which includes p38 MAPK.
To fully elucidate the mechanisms that support cisplatin
resistance, we examined the signaling kinases downstream
of EGFR in HT29 and SW620 cell lines. HT29 harbors
BRAFV600E and PI3KP449T mutations, while SW620 har-
bors a KRASG12V mutation all of which could provide
independent constitutive signaling, affecting cisplatin
response (Ahmed et al., 2013). The response of each of the
cell lines to the drug combinations and or inhibitors was
directly related to activation of the signaling pathway con-
trolled by PrPC/EGFR and the nuclear levels of KLF5
protein. Western blot protein expression analysis and den-
sitometry of independent experiments (Fig. S5) provided a
heatmap of relative expression changes standardized for
housekeeping protein expression. Generally, in the HT29
cells we observed changes in PrPC expression under vari-
ous conditions (Fig. 2C) and reduced EGFR and AKT
signaling although AKT expression was enhanced across
most conditions (Fig. 2D), indicating a dominant pathway
via PI3K rather than BRAF. In contrast, P38MAPK
expression was generally repressed. Interestingly, phos-
hpo-p38 signaling was repressed by the combination of
cisplatin/gefitinib but not by cisplatin/PrPCKD, indicating
two different mechanisms of signaling controlled by
EGFR and PrPC in HT29 cells (Fig. 2D). A different
overall profile was observed in SW620 cells with robust
EGFR signaling across a number of conditions, of note in
response to cisplatin and PrPC knockdown (Fig. 2E) Sim-
ilarly, enhanced activation in response to cisplatin/gefi-
tinib/p38i was seen with reduced EGFR signaling, KLF5,
and FOXO3a protein levels in the nucleus (Fig. 2E). A
more robust p38 signaling response via phospho-p38 was
observed in SW620 under various conditions, indicating a
more dominant BRAF/p38 axis rather than PI3K
(Fig. 2F). We evaluated whether targeting of the BRAF/
p38 axis using a single dose of p38i could induce cell death
over the extended period of 144 h of exposure. No signifi-
cant cell death was observed even with sustained signaling
response as indicated by induction of PrPC protein expres-
sion (Fig. S6).
High expression levels of KLF5 are a determinant of
resistance to cisplatin in ovarian and breast cancers (Dong
et al., 2013; Li et al., 2017) and corresponded with
enhanced EGFR signaling in both colorectal cell lines
(Fig. 2C,E). The only combination therapy able to achieve
low nuclear levels of KLF5 in both cell lines was cisplatin/
gefitinib/p38i (Fig. 2D,F), which was also an effective
cytotoxic combination (Fig. 2A). In HT29 cells, the
absence of p38 inhibition in the cisplatin/gefitinib combi-
nation induced nuclear levels of KLF5, still demonstrating
the requirement for targeting the p38 pathway and BRAF
signaling even though it is not the dominant signaling
pathway. In SW620 cells, in the absence of p38 inhibition
the cisplatin/gefitinib combination repressed nuclear levels
of KLF5, indicating the targeting of p38 may not be
required in this setting (Fig. 2F).
3.4. Knockdown of KLF5 sensitizes to cisplatin
more effectively than knockdown of PrPC
We confirmed significantly decreased cDNA gene
expression of KLF5 with the combination of cisplatin/
gefitinib/p38i and significantly increased gene expres-
sion of KLF5 in response to cisplatin/PrPCKD/p38i in
both cell lines (Fig. 3A,B). KLF5 typically supports
proliferation in nontransformed cells, providing a
Fig. 2. Analysis of signaling downstream of PrPC/EGFR by protein expression. (A) HT29, SW620, and T84 cell line viability in response to
cisplatin treatment with or without gefitinib and p38 MAPK inhibitor. Cell viability determined by MTS (% viability relative to DMSO  SEM
and significance measured by two-tailed Student’s t-test *P < 0.05) (B) Cell viability of HT29 cells in response to p38 MAPK inhibitor with or
without PrPC knockdown and gefitinib in the absence of cisplatin. Cell viability determined by MTS (% relative to DMSO  SEM and
significance measured by two-tailed Student’s t-test *P < 0.05). (C) Protein expression analysis of the nuclear and cytosol fractions from
HT29 cells from each treatment group. Histone H3 and a-tubulin are used as loading controls for nuclear and cytosolic fractions,
respectively. (D) Average densitometry of three independent isolates standardized to the controls and finally expressed as relative change to
untreated cells. (E) Protein expression analysis of the nuclear and cytosol fractions from SW620 cells from each treatment group. Histone
H3 and a-tubulin are used as loading controls for nuclear and cytosolic fractions, respectively. (F) Average densitometry of two independent
isolates standardized to the controls and finally expressed as relative change to untreated cells.
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growth advantage (Bateman et al., 2004; Chancheva-
lap et al., 2004; Sun et al., 2001), and has been shown
to induce cisplatin resistance in breast cancer (Li et al.,
2017). In contrast to these findings, KLF5 has been
shown to have growth inhibitory properties in colon
cancer-derived cells (Bateman et al., 2004). We found
that knockdown of KLF5 (Fig. 3C) sensitized to cis-
platin to a greater extent than PrPC knockdown alone
(Fig. 3D) or knockdown of PrPC and KLF5 together
in HT29 cells (Fig. 3E) and SW620 cells (Fig. 3F). We
suggest that resistance to platinum-based therapy
could be determined by the interplay between PrPC,
EGFR, and resulting signaling to increase KLF5
expression levels and nuclear localization (Fig. 3G).
We find that constitutively activating mutations result
in a dominant signaling pathway but are not necessar-
ily the pathway to be targeted to resensitize to the
drug of choice, in this case cisplatin.
3.5. Activation of PrPC/FOXO/KLF5 axis correlates
with platinum resistance and poor outcome in
patients
We next examined changes in PrPC, FOXO3a, and
KLF5 expression levels during progression from pri-
mary colorectal cancer to liver metastasis in matched
Fig. 3. Knockdown of KLF5 sensitizes cells to cisplatin. (A) Relative mRNA expression levels of PRNP and KLF5 in response to indicated
treatment HT29 cells and (B) SW620 cells. (Data normalized to GAPDH  SEM and significance measured by two-tailed Student’s t-test
***P < 0.001) (C) Targeted knockdown of KLF5 in HT29 and SW620 cells. (D) Targeted knockdown of PrPC in HT29 and SW620 cells. (E)
Cisplatin IC50 in HT29 cells and (F) SW620 cells following PrPC, KLF5, or double knockdown determined by MTS. (Data compared to SCR
control  SEM and significance measured by two-tailed Student’s t-test ***P < 0.001, *P < 0.05) SCR, nontargeting scrambled; PRNPsi,
PrPC knockdown; KLF5si, KLF5 knockdown; DKO, double (PrPC and KLF5) knockdown. (G) A schematic showing the proposed EGFR
signaling cascade in cisplatin-sensitive and cisplatin-resistant cells. The point of action of cisplatin, gefitinib, and p38 MAPK inhibitor is
indicated.
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patient samples, to determine a signaling response to
platinum-based therapy. Immunohistochemistry of
tumor samples displays a range of positive and nega-
tive staining in the cytoplasm for PrPC, FOXO3a, and
KLF5 (Fig. 4A). When chemotherapy history was
taken into account, metastatic samples from three of
the 11 patients exhibited decreased PrPC, increased
FOXO3a, and decreased or no change in KLF5 com-
pared with primary samples (Fig. 4B), signifying a
platinum-sensitive profile in the metastases. These
three patients received oxaliplatin as part of their adju-
vant therapy, which resulted in a median survival of
34 months (Table 1). Of the remaining eight patients,
two patients received oxaliplatin, and their metastases
displayed a resistance profile of increased PrPC,
decreased FOXO3a, and increased KLF5 expression,
resulting in a poorer outcome than patients with a sen-
sitive profile with median survival 21 months
(Table 1). Of the last six patients, four did not receive
platinum-based therapy and two had only recently
commenced therapy at the time of sample collection.
We find that expression of KLF5 is an important
determinant of cellular response in BRAF-mutant cell
line HT29 and in patient outcomes for platinum-based
therapy. KLF5 is upregulated in response to mutant
KRAS, resulting in increased rate of proliferation and
anchorage-independent growth (Nandan et al., 2008);
however, a link between chemoresistance mediated by
KLF5 expression and BRAF mutation is yet to be
described. We examined a cohort of BRAF-wild-type
cancers and BRAF-mutant cancers, further stratified
by microsatellite instability status (Fig. 4C), and found
KLF5 to be significantly elevated in BRAF-mutant
cancers (Fig. 4D). We did not observe any significant
difference in PrPC expression.
To evaluate the potential of the PrPc/FOXO3a/
KLF5 axis to be prognostic in aggressive colon cancer,
we examined a cohort of 46 Grade 3 patients for sur-
vival rates based on expression. Each of the genes in
the axis displayed significant stratification for poor
patient survival when overexpressed (Fig. 4E). Of note,
FOXO3a gene expression displayed the most signifi-
cance, which was not bettered by the three-gene signa-
ture; however, we observed some variability in
FOXO3a protein expression in our patient samples
and suggest that the three-gene signature would be a more
robust prognostic predictor than a single gene (Fig. 4E).
4. Discussion
Epidermal growth factor receptor is a potential target
for metastatic colorectal cancer with safety, tolerabil-
ity, and pharmacokinetics being explored in multiple
clinical trials. Potential efficacy and clinical outcome
are determined by cellular molecular characteristics,
including EGFR binding partners, cellular genetic
aberrations, and available signal transduction path-
ways. In neuronal cells, PrPC is a binding partner of
EGFR creating a multimeric complex that colocalizes
in the lipid rafts, which can be immunoprecipitated
under endogenous levels of expression (Llorens et al.,
2013). We observe colocalization in colorectal cancer
cells. PrPC has been shown to interact with two com-
ponents of the EGFR macromolecular complex, Grb2
and p-Src, revealing an active signaling complex that
regulates both AKT and MAP kinase pathways. Upon
depletion of PrPC, we observed reduced AKT signal-
ing, signifying an important role for PrPC in activation
of EGFR signaling (Llorens et al., 2013). The conse-
quences of reduced signaling resulted in reduced
nuclear KLF5. KLF5 is present primarily in the
epithelial cells lining the bases of the crypts and has
been linked with cisplatin resistance in breast cancer
(Li et al., 2017). This supports the hypothesis that
PrPC serves as a binding partner of EGFR and proto-
oncogene supporting colorectal cell proliferation and
response to therapy via control of gene expression.
Chemosensitivity or chemoresistance is determined
by the combination of genetic aberrations within the
cancer cell that drive the dominant signaling. Recently,
p38 MAPK and FOXO3a each have been described as
potential factors in colorectal chemoresistance and
possible drug targets (Grossi et al., 2014). The FOXO
family of transcription factors are regulated by phos-
phorylation, ubiquitination, and/or acetylation, which
affect subcellular localization and stability. As such,
they are involved in a number of cellular processes
including those observed to involve PrPC (Brunet
et al., 1999; van der Horst et al., 2006; Motta et al.,
2004). FOXO3a has been demonstrated to be a key
mediator of the cytotoxic effect of cisplatin (Fernandez
de Mattos et al., 2008; Germani et al., 2014). In cis-
platin-sensitive colorectal cancer cells, FOXO3a is
dephosphorylated and undergoes nuclear translocation
and target genes are expressed or repressed. However,
this mechanism is compromised in those cell lines
resistant to cisplatin (Fernandez de Mattos et al.,
2008). Of note, in colorectal cancer cells, signaling via
p38MAPK represses FOXO3a activity and inhibition
of p38MAPK has been shown to increase the effect of
cisplatin by inducing FOXO3a dephosphorylation
(Germani et al., 2014). In a neuroblastoma cancer
model, there is evidence of PrPC promoting chemore-
sistance by inhibition of FOXO3a (Liu et al., 2013).
Therefore, we hypothesized that cisplatin resistance
mediated by PrPC could be overcome by targeting p38
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Fig. 4. The PrPC/FOXO3a/KLF5 axis expression correlates with colorectal cancer patient progression and is a marker for outcome. (A)
Representative images of negative and positive immunohistochemical staining of PrPC, FOXO3a, and KLF5 from liver metastases, scale bar
100 lM. (B) Changes in positive staining percentages for PrPC, FOXO3a, and KLF5 in 11 matched primary colorectal cancer and liver
metastases. (C) Representative images of negative and positive KLF5 staining of BRAF-mutant microsatellite stable (MSS) and BRAF-mutant
microsatellite unstable (MSI) cancers, scale bar 100 lM. (D) Comparison of PrPC and KLF5 in BRAF-wild-type and BRAF-mutant cancers,
stratified by microsatellite instability (significance measured by two-tailed Student’s t-test **P < 0.005). (E) Gene expression correlation with
overall survival in 46 patients with aggressive Grade 3 colon cancer (significance determined by logrank test).
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MAPK. We observed PrPC depletion alone did not sen-
sitize HT29 or SW620 cells; however, in combination
with p38 inhibition, we significantly sensitized HT29
cells to cisplatin. This suggests PrPC and p38-MAPK
pathway are contributors to the cisplatin resistance
observed in cell lines that express high levels of PrPC.
Mutations in either KRAS or BRAF drive col-
orectal cancers and predominate complementary
pathways from EGFR that converge on FOXO3a.
We found that mutations in upstream kinases such
as KRAS or PI3K influenced the capability to acti-
vate p38MAPK downstream and there was an
importance to target p38MAPK to sensitize to cis-
platin with gefitinib in either cell line. However,
overexpression of PrPC induces p-AKT promoting
cell survival and chemoresistance (Llorens et al.,
2013), which was enhanced in both colorectal cell
lines by targeting p38 MAPK resulting in increased
nuclear KLF5. This demonstrates that PrPC may be
signaling independent of EGFR. The targeting of
p38 MAPK with additional depletion of PrPC
reduced p-AKT and, however, retained nuclear
KLF5 levels in both cell lines. This reveals that high
nuclear KLF5 expression and the associated cisplatin
resistance phenotype are driven predominantly by
p38 MAPK signaling and not PrPC-mediated induc-
tion of p-AKT. This is supported by the loss of col-
orectal cell viability in the presence of gefitinib/p38i
but not PRNPsi/p38i and reduced nuclear KLF5
expression with gefitinib/p38i/cisplatin but not
PRNPsi/p38i/cisplatin. Of note, the HT29 colorectal
cell line studied harbors a PI3KP449T mutation,
which is likely to support AKT signaling to some
extent independent of PrPC status. PI3K mutations
have been shown to provide enhanced sensitivity to
gefitinib, with the isogenic breast cancer cell lines
harboring either PI3KH1047R or PI3KE545K mutations
3.5 and 6.5 times more sensitive respectively to gefi-
tinib than wild-type cells (Glaysher et al., 2014).
PI3K status has been identified as a key factor for
response to anti-EGFR treatment in metastatic col-
orectal cancer; however, we suggest that PrPC/EGFR
may have utility in p38MAPK driven and BRAF
colorectal cancers (Lievre et al., 2017).
The prognostic value of PrPC/EGFR is related to
analyzing the changes in expression of the PrPC-
FOXO3a-KLF5 axis. As a gene set, the prognostic
profile is very similar to that of KLF5 alone, but
with slightly more statistical power. We found that
patient outcomes were more favorable with repres-
sion of this axis rather than activation, resulting in
a difference in median survival of 13 months. This is
a meaningful difference as the current clinical
outcomes based on nonprognosticated therapy are
incremental at best. For example, the PRIME trial
of 656 patients comparing the standard platinum-
based FOLFOX therapy with and without the tar-
geting of EGFR signaling cascade demonstrated that
targeting EGFR resulted in a significantly enhanced
primary survival of 1.6 months and enhanced sec-
ondary survival of 4.2 months (Haraldsdottir and
Bekaii-Saab, 2013). If patients on this trial were
stratified for cancers that were dominant for signal-
ing via the PrPC-FOXO3a-KLF5 axis they could be
switched off FOLFOX therapy, resulting in high
rates of survival. With such a high proportion (50–
70%) of acquired clinical resistance to platinum-
based therapy in colorectal cancer, we propose our
findings have potential utility in prognosis and the
ability to help track potential chemoresistance and
metastatic relapse.
5. Conclusion
There is a need to identify the correlative molecular
and pathologic markers that can predict patient
outcome and guide therapy. We believe the PrPC-
FOXO3a-KLF5 axis represents a novel molecular
predictor of cisplatin resistance and associated
metastatic relapse in aggressive colorectal cancer.
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